Applied Therapeutics Soars 19.27% on Clinical Trial Data

On May 21, 2025, Applied Therapeutics' stock surged by 19.27% in pre-market trading, marking a significant rise for the clinical-stage biopharmaceutical company.

Analysts have shown a mixed outlook on Applied Therapeutics. While some analysts have given a "Buy" rating with a 12-month price target of $6.10, others have reiterated a neutral stance, giving a "Hold" rating. The 12-month price target for the stock ranges from $1.50 to $14, reflecting a wide range of expectations among analysts.

Applied Therapeutics has been actively engaged in clinical trials, with recent presentations of full 12-month clinical results and new topline data from the INSPIRE Phase 2/3 trial of Govorestat in CMT-SORD. These developments have been closely watched by investors, contributing to the stock's volatility.

The company's focus on developing novel drug candidates for unmet medical needs continues to drive interest in its stock. However, the mixed results from recent clinical trials and the neutral stance from some analysts have tempered investor enthusiasm, leading to fluctuations in the stock price.